Protein Kinase C Epsilon Type - Pipeline Review, H2 2019

Publication ID:

GMD1219161

Publication Date:

December 27, 2019

Pages:

Publisher:

Global 麻豆原创s Direct

Countries:

Global [1]

USD 3,500.00

Drug Pipeline [2]

Pharma & Healthcare [3]

Description:

Protein Kinase C Epsilon Type - Pipeline Review, H2 2019

Summary

According to the recently published report 'Protein Kinase C Epsilon Type - Pipeline Review, H2 2019'; Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 9 molecules.

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine- and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.

The report 'Protein Kinase C Epsilon Type - Pipeline Review, H2 2019' outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 9 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology which include indications Traumatic Brain Injury, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Alcohol Addiction, Alzheimer's Disease, Depression, Dry (Atrophic) Macular Degeneration, Fragile X Syndrome, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemia Reperfusion Injury, Ischemic Stroke, Multiple Sclerosis, Neurology, Parkinson's Disease, Rett Syndrome and Stroke.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
- The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it鈥檚 most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents:

Table of Contents
List of Tables
List of Figures
Introduction
Global 麻豆原创s Direct Report Coverage
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development
BryoLogyx Inc
CHS Pharma Inc
Neurotrope Bioscience Inc
VM Discovery Inc
Young Therapeutics LLC
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles
Bryostatin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PKC Epsilon for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PRKCE for HIV and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulindac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMD-2202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
Featured News & Press Releases
Sep 10, 2019: Neurotrope Alzheimer鈥檚 Phase II trial fails to meet endpoints
Aug 13, 2019: Neurotrope announces publication highlighting the potential of bryostatin as a unique neurorestorative therapy
Jul 15, 2019: Neurotrope concludes data collection in confirmatory phase 2 clinical trial of moderately severe to severe Alzheimer's Disease
Jul 11, 2019: Neurotrope to present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented
Jun 03, 2019: Neurotrope's president and chief scientific officer to present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019
Mar 21, 2019: Neurotrope CEO statement on development of Bryostatin
Mar 14, 2019: Neurotrope doses last patient in Alzheimer鈥檚 trial
Dec 17, 2018: Neurotrope announces publication of phase 2 study of Bryostatin-1 in moderate to severe alzheimer's disease in the Journal of Alzheimer's Disease
Oct 24, 2018: Neurotrope presents updated phase 2 data of Bryostatin-1 in moderate to severe Alzheimer's disease at the 11th edition of CTAD
Sep 26, 2018: Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer鈥檚 Disease (CTAD2018)
Jul 25, 2018: At AAIC 2018, Neurotrope presents additional clinical results showing cognitive improvement in phase 2 data assessing Bryostatin-1 in moderate-to-severe alzheimer鈥檚 patients
Jul 16, 2018: Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimers Disease
Jul 01, 2018: Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting
May 07, 2018: Neurotrope In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimers Patients
Jan 05, 2018: Neurotropes Bryostatin Improves Cognition in Patients with Advanced Alzheimers Disease Based on Further Analysis of Phase 2 Clinical Trial Data
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by BryoLogyx Inc, H2 2019
Pipeline by CHS Pharma Inc, H2 2019
Pipeline by Neurotrope Bioscience Inc, H2 2019
Pipeline by VM Discovery Inc, H2 2019
Pipeline by Young Therapeutics LLC, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List of Figures
List of Figures
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Companies Mentioned:

BryoLogyx Inc
CHS Pharma Inc
Neurotrope Bioscience Inc
VM Discovery Inc
Young Therapeutics LLC

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.